TL;DR
The first weight-loss drug to cut heart attacks in people who don't even have diabetes.
What is it? A once-weekly GLP-1 injection from Novo Nordisk. Sold as Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral).
What does it do? Quiets hunger in the brain, slows stomach emptying, releases insulin only when blood sugar climbs. Appetite drops. Portion sizes shrink.
Does the evidence hold up? Rare case where the answer is yes. STEP-1: 14.9% body weight loss at 68 weeks. SELECT, a 17,604-person trial in non-diabetics, cut major heart events by 20%. Fifty-plus completed RCTs.
Who uses it? Endocrinologists, cardiologists, obesity medicine, and a notable chunk of compounded-semaglutide clinics.
Bottom line? Clinically proven. Expensive. Worth it for the right patient.
What It Is
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a 31-amino-acid peptide analog of the naturally occurring incretin hormone GLP-1(7–37). Developed by Novo Nordisk and first approved by the FDA in 2017, it has become one of the most consequential pharmaceutical developments of the 21st century. The molecule is engineered with three key modifications: an α-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, an arginine substitution at position 34, and a C-18 fatty diacid chain attached at position 26 via a linker that binds albumin in the blood. This albumin binding extends the plasma half-life from approximately 2 minutes (native GLP-1) to roughly 7 days, enabling once-weekly dosing.
What makes semaglutide historically significant is that it was the first drug to demonstrate both clinically meaningful sustained weight loss and cardiovascular mortality benefit in large randomized controlled trials. Before semaglutide, no pharmacological intervention for obesity had cleared both of those bars simultaneously. The STEP trial program showed 15–17% body weight reduction at therapeutic doses, and the SELECT trial (n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events in overweight and obese adults without diabetes. These results fundamentally shifted the medical conversation about obesity from a condition of willpower to a condition of biology amenable to pharmacological intervention.
Semaglutide is available in three branded formulations: Ozempic (injectable, approved for type 2 diabetes), Wegovy (injectable, approved for chronic weight management and — as of March 2024 — cardiovascular risk reduction in overweight/obese adults with established CVD), and Rybelsus (oral tablet, approved for type 2 diabetes). All three contain the same semaglutide molecule at different doses and regulatory indications. Compounded semaglutide has also been widely available through 503A and 503B pharmacies through the FDA-declared shortage window, at substantially lower cost than branded formulations.
Mechanism of Action
Semaglutide is a selective GLP-1 receptor agonist — it activates GLP-1 receptors throughout multiple organ systems while having no direct activity at GIP receptors. This distinguishes it from dual agonists like tirzepatide. GLP-1 receptors are expressed far beyond the pancreas — they are found in the brain, heart, kidneys, vasculature, and gastrointestinal tract.
- Pancreatic GLP-1R activation (glucose-dependent insulin secretion) — Semaglutide binds GLP-1 receptors on pancreatic β cells, potentiating glucose-dependent insulin secretion via cAMP-PKA-EPAC2 signaling. This insulin secretion is glucose-dependent: it only enhances insulin release when blood glucose is elevated, which is why GLP-1 agonists carry minimal hypoglycemia risk as monotherapy. Semaglutide simultaneously suppresses glucagon secretion from α cells.
- Hypothalamic appetite regulation (POMC/CART and NPY/AgRP pathways) — GLP-1 receptors in the arcuate and paraventricular nuclei mediate central appetite suppression. Semaglutide activates anorexigenic POMC/CART neurons while inhibiting orexigenic NPY/AgRP neurons, reducing hunger signaling at a neuroendocrine level. Patients consistently report reduced "food noise." fMRI studies show reduced activation in brain reward centers in response to food cues.
- Brainstem satiety signaling (NTS and area postrema) — GLP-1 receptors in the nucleus tractus solitarius and area postrema integrate peripheral satiety signals with central appetite regulation. Semaglutide enhances the satiating effect of meals through these brainstem circuits. The area postrema lies outside the blood-brain barrier — it is a chemoreceptor trigger zone, which is why nausea is the most common side effect.
- Delayed gastric emptying — Semaglutide slows gastric emptying via vagal afferent GLP-1 receptor activation, prolonging postprandial satiety and contributing to reduced caloric intake. The effect is most pronounced early in treatment and partially attenuates with chronic dosing.
- Cardiovascular protection (endothelial function, anti-inflammatory) — GLP-1 receptors on vascular endothelial cells and cardiomyocytes mediate direct cardiovascular effects independent of weight loss. Semaglutide improves endothelial function via eNOS activation, suppresses vascular NF-κB signaling in macrophages, decreases arterial stiffness, and improves atherogenic lipid profiles. The SELECT trial confirmed these effects translate to hard clinical endpoints in non-diabetic patients.
- Renal hemodynamic effects (natriuresis and tubuloglomerular feedback) — GLP-1 receptors in the proximal renal tubule promote natriuresis and reduce intraglomerular pressure through tubuloglomerular feedback modulation. The FLOW trial demonstrated clinically meaningful kidney protection — 24% reduction in CKD composite progression.
- Albumin binding and extended pharmacokinetics — The C-18 fatty diacid sidechain binds serum albumin non-covalently. Approximately 99% of circulating semaglutide is albumin-bound at steady state, extending half-life to ~168 hours, reducing renal clearance, and providing a sustained steady-state drug level without peak-trough fluctuations.
- Hepatoprotective effects (lipid metabolism and inflammation) — GLP-1 receptor activation reduces hepatic de novo lipogenesis, increases fatty acid oxidation, and attenuates hepatic stellate cell activation. Phase 2 data showed significant resolution of steatohepatitis with semaglutide (PMID 33185364).
- Neuroprotective potential (neuroinflammation and amyloid) — GLP-1 receptors are expressed on neurons and microglia. Preclinical data show semaglutide reduces neuroinflammation, microglial activation, and amyloid-β burden in Alzheimer's models. Phase 3 EVOKE/EVOKE+ trials are investigating semaglutide for early Alzheimer's disease.
- GLP-1 selectivity vs dual GLP-1/GIP agonism — Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide activates both GLP-1 and GIP receptors; retatrutide adds glucagon receptor agonism. Multi-receptor agonists produce greater absolute weight loss in trials but semaglutide has the deepest cardiovascular and renal outcomes evidence base.
What the Research Shows
Semaglutide has one of the most extensive clinical evidence bases of any drug developed in the past two decades. Multiple large-scale Phase 3 randomized controlled trial programs have established efficacy across obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, and liver disease.
- Obesity (STEP program) — STEP 1 (n=1,961) demonstrated 14.9% mean body weight loss vs 2.4% with placebo at 68 weeks. STEP 3 showed 16.0% weight loss with intensive behavioral therapy. STEP 5 (104 weeks) demonstrated sustained 15.2% weight loss. STEP 8, a direct comparison against liraglutide 3.0 mg, showed roughly double the weight loss (15.8% vs 6.4%).
- Cardiovascular outcomes (SELECT) — 17,604 overweight or obese adults aged 45+ with established CVD but without diabetes. Semaglutide 2.4 mg weekly reduced the composite primary endpoint of MACE by 20% vs placebo over a median 39.8 months (HR 0.80; PMID 37952131). First cardiovascular mortality benefit for any weight management drug in non-diabetic patients.
- Chronic kidney disease (FLOW) — 3,533 patients with T2D and CKD. Semaglutide 1.0 mg weekly reduced the primary composite kidney endpoint by 24% (HR 0.76; PMID 38785209). Stopped early by DSMB for efficacy.
- Type 2 diabetes (SUSTAIN program) — SUSTAIN 6 (n=3,297) demonstrated 26% reduction in MACE in T2D patients with high CV risk (PMID 27633186). Across the program, semaglutide showed superior HbA1c reduction vs sitagliptin, exenatide, dulaglutide, insulin glargine, and canagliflozin.
- Oral formulation (PIONEER program) — PIONEER 1 showed significant HbA1c reduction with oral semaglutide 14 mg daily vs placebo (PMID 31186300). The oral formulation uses the absorption enhancer SNAC to enable GI uptake despite peptide structure.
- Liver disease (MASH/NASH) — Phase 2 showed semaglutide 0.4 mg daily resolved steatohepatitis in 59% vs 17% with placebo (PMID 33185364). Phase 3 trials are ongoing.
- Alzheimer's disease (EVOKE) — Phase 3 trials of oral semaglutide in early Alzheimer's. Readouts pending.
- Head-to-head vs liraglutide (STEP 8) — Semaglutide 2.4 mg vs liraglutide 3.0 mg; semaglutide achieved 15.8% vs 6.4% body weight reduction at 68 weeks (PMID 35015037).
- Durability (STEP 5) — Two-year data showing sustained weight loss of 15.2% at 104 weeks, confirming durability beyond one year (PMID 36216945).
Critical Context — Research Sponsorship
The majority of semaglutide's clinical trial program has been sponsored by Novo Nordisk. While the trials are large, well-designed, and published in top-tier journals, manufacturer sponsorship is a standard consideration when evaluating any pharmaceutical evidence base. Independent replication and post-marketing surveillance continue to corroborate the trial findings. The weight regain data after discontinuation (STEP 1 extension) were transparently published, demonstrating that the drug works while taken — it is not a cure for obesity.
Human Data
Semaglutide has been studied in over 50 completed randomized controlled trials enrolling tens of thousands of participants. Key landmark trials with specific outcomes:
- STEP 1 (NCT03548935) — 1,961 adults with BMI ≥30 (or ≥27 with comorbidity), no diabetes. Semaglutide 2.4 mg weekly vs placebo for 68 weeks. Primary endpoint: 14.9% mean weight loss vs 2.4% placebo. 86.4% lost ≥5% body weight. 32% lost ≥20%. NEJM 2021 (PMID 33567185).
- STEP 2 (NCT03552757) — 1,210 adults with overweight/obesity and T2D. Semaglutide 2.4 mg weekly achieved 9.6% vs 3.4% placebo at 68 weeks. Lancet 2021 (PMID 33667417).
- STEP 3 (NCT03611582) — 611 adults with overweight/obesity, no diabetes, semaglutide 2.4 mg + intensive behavioral therapy. 16.0% vs 5.7% placebo at 68 weeks. JAMA 2021 (PMID 33625476).
- STEP 4 (NCT03548987) — Continued weekly semaglutide vs placebo for weight-loss maintenance after 20-week run-in. JAMA 2021 (PMID 33755728).
- STEP 5 (NCT03693430) — 304 adults; 104-week data demonstrating sustained −15.2% vs −2.6% placebo, confirming durability. Nat Med 2022 (PMID 36216945).
- STEP 8 (NCT04074161) — 338 adults; head-to-head semaglutide 2.4 mg vs liraglutide 3.0 mg. 15.8% vs 6.4% at 68 weeks. JAMA 2022 (PMID 35015037).
- SELECT (NCT03574597) — 17,604 adults ≥45, BMI ≥27, established CVD, no diabetes. Semaglutide 2.4 mg for median 39.8 months. 20% reduction in 3-point MACE (HR 0.80; PMID 37952131).
- FLOW (NCT03819153) — 3,533 patients with T2D and CKD. Semaglutide 1.0 mg weekly. Primary composite kidney endpoint reduced by 24% (PMID 38785209).
- SUSTAIN 6 (NCT01720446) — 3,297 patients with T2D and high CV risk. Semaglutide 0.5 or 1.0 mg weekly for 104 weeks. 26% reduction in 3-point MACE (PMID 27633186).
- PIONEER 1 (NCT02906930) — Oral semaglutide monotherapy in T2D (PMID 31186300).
- MASH Phase 2 (NCT02970942) — Semaglutide 0.4 mg daily in NASH; 59% histological resolution (PMID 33185364).
Additional Phase 3 trials are underway or recently completed for MASH/NAFLD, Alzheimer's disease (EVOKE and EVOKE+), heart failure with preserved ejection fraction, and peripheral artery disease.
Dosing from the Literature
FDA-approved dosing schedules for branded formulations. All injectable doses are once weekly subcutaneous.
| Indication | Brand | Titration | Maintenance | Notes |
|---|
| Type 2 Diabetes | Ozempic | 0.25 mg ×4 wks → 0.5 mg | 0.5, 1.0, or 2.0 mg weekly | May increase to 2.0 mg if additional glycemic control needed |
| Obesity | Wegovy | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg (16-wk escalation) | 2.4 mg weekly | Each titration step is 4 weeks. Do not skip steps. |
| T2D (oral) | Rybelsus | 3 mg daily ×30 days → 7 mg | 7 mg or 14 mg daily | Empty stomach with ≤4 oz water, 30 min before food |
| Compounded | Various | Varies by provider | Typically 0.25–2.5 mg weekly | Follow same titration principles as branded. See reconstitution below. |
Titration Is Critical
Semaglutide must be titrated slowly. Starting at the full maintenance dose causes severe nausea, vomiting, and GI distress in most patients. The 16-week Wegovy escalation schedule exists because GLP-1 receptor desensitization in the area postrema requires time. Compounded versions that skip titration steps or start too high are a common source of adverse events and unnecessary discontinuation. If GI side effects are intolerable at any step, hold the current dose for an additional 4 weeks before escalating.
Reconstitution & Storage
Brand-name semaglutide (Ozempic, Wegovy) comes in pre-filled injection pens that require no reconstitution. The information below applies to compounded semaglutide, which is typically supplied as lyophilized powder in 5 mg or 10 mg vials.
| Vial Size | BAC Water | Concentration | 0.25 mg Dose | 0.5 mg Dose | 1.0 mg Dose |
|---|
| 5 mg | 2 mL | 2.5 mg/mL | 10 units (0.10 mL) | 20 units (0.20 mL) | 40 units (0.40 mL) |
| 10 mg | 2 mL | 5.0 mg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) | 20 units (0.20 mL) |
- Reconstitution — Inject BAC water slowly down the inside vial wall at 45°. Swirl gently until fully dissolved — do not shake. Solution should be clear and colorless.
- Storage (reconstituted) — Refrigerate at 2–8°C and use within 28 days. Do not freeze. Protect from light. Discard if cloudy, particulate, or color-changed.
- Storage (lyophilized) — Unreconstituted powder is stable refrigerated for 24+ months. Short-term room-temperature storage acceptable.
- Brand pens (Ozempic/Wegovy) — Refrigerated before first use. After first use, room temperature up to 30°C or refrigerated for up to 56 days. Do not freeze.
- Injection technique — SubQ in abdomen, thigh, or upper arm. Rotate sites weekly. 29–31G ½-inch insulin syringe for compounded vials.
→ Use the Kalios Dosing Calculator for exact syringe units
Side Effects & Risks
Important
Side effects are well-documented from large trials — nausea, GI distress, rare pancreatitis. Worth discussing with your doctor before starting or switching.
Semaglutide's safety profile is well-characterized from large clinical trials. The most common adverse events are gastrointestinal:
- Nausea — 40–45% in STEP trials. Typically worst during titration and improves over 4–8 weeks as area postrema GLP-1 receptors desensitize.
- GI distress — Diarrhea ~30%, vomiting ~25%, constipation ~24%, abdominal pain ~20%. Primary reason for discontinuation (~7% dropout in STEP 1).
- Pancreatitis — Rare but serious. All GLP-1 agonists carry this warning. Discontinue immediately if severe persistent abdominal pain radiating to the back. Check amylase/lipase. Do not restart after confirmed pancreatitis.
- Thyroid C-cell tumors (boxed warning) — Based on rodent carcinogenicity studies. No confirmed causal link in humans. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.
- Gallbladder events — Cholelithiasis and cholecystitis risk increased with rapid weight loss. Highest in first 6–12 months. Counsel patients on RUQ pain after fatty meals.
- Lean mass loss — DEXA data suggest 25–40% of total weight lost may be lean mass. Countermeasures: resistance training 3–4×/week, protein 1.0–1.2 g/kg target body weight, creatine.
- Rebound weight gain — STEP 1 extension: ~two-thirds of weight regained within one year of discontinuation. Chronic-therapy paradigm, similar to antihypertensives.
- Facial volume loss ("Ozempic face") — Not a medication side effect per se; feature of any large rapid weight loss. More gradual titration reduces severity.
- Mental health — Post-marketing signals of suicidal ideation prompted FDA investigation. Large-scale trial data (SELECT, n=17,604) did not show increased rates of depression or suicidal ideation. Monitoring remains recommended, particularly with pre-existing psychiatric conditions.
- WADA status — Not currently on the WADA prohibited list. Athletes in weight-class sports should verify federation status.
- Compounded product purity — In 2023, FDA warned about compounded products containing semaglutide sodium salt with uncertain bioequivalence. Use licensed 503A/503B pharmacies with third-party COAs.
- Drug interactions — Delayed gastric emptying affects oral drug absorption, particularly narrow-therapeutic-index medications (warfarin, levothyroxine, oral contraceptives). Insulin and sulfonylureas: hypoglycemia risk — dose reduction likely needed.
Bloodwork & Monitoring
Semaglutide is an FDA-approved medication with established monitoring guidelines.
- HbA1c and fasting glucose — Track glycemic improvement. Non-diabetics should monitor periodically.
- Lipid panel — LDL, HDL, triglycerides, Lp(a). Expect broad improvement; SELECT showed significant triglyceride and CRP reduction.
- Liver enzymes (ALT, AST) — Monitor hepatic function; improvement commonly observed in MASH context.
- Kidney function (BUN, creatinine, eGFR, UACR) — Critical in CKD or T2D context per FLOW protocol.
- Thyroid function (TSH) — Baseline. Calcitonin monitoring if neck mass or hoarseness develops.
- Body composition (DEXA) — Baseline and every 6–12 months. Critical for monitoring sarcopenia risk.
- Amylase and lipase — Check if severe abdominal pain develops.
- Nutritional markers (B12, iron, ferritin, vitamin D) — Every 6 months on chronic therapy.
- Inflammatory markers (hsCRP) — SELECT demonstrated significant hsCRP reduction.
Commonly Stacked With
Semaglutide and tirzepatide should never be used simultaneously — they are alternative GLP-1 therapies with overlapping mechanisms. Patients who plateau on semaglutide sometimes switch to tirzepatide's dual GLP-1/GIP agonism for additional weight loss.
Men on TRT who add semaglutide lose fat while testosterone's anabolic effects help preserve lean mass — directly addressing semaglutide's biggest limitation. One of the most common combinations in telehealth optimization clinics.
Some users add BPC-157 during titration for cytoprotective effects on gastric mucosa to mitigate nausea. Mechanistic rationale; no clinical trial data on this specific combination.
GH secretagogue stack added by some practitioners to support lean mass preservation during semaglutide-driven weight loss. No clinical data on this specific combination; mechanistic rationale only.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
Semaglutide is FDA-approved under multiple brand names: Ozempic (December 2017, type 2 diabetes), Rybelsus (September 2019, oral T2D), and Wegovy (June 2021, chronic weight management). Wegovy received supplemental approval in March 2024 to reduce cardiovascular risk in overweight/obese adults with established CVD, based on SELECT.
Compounded semaglutide was widely available through 503A and 503B pharmacies during the FDA shortage window. Novo Nordisk has aggressively pursued legal action against compounding pharmacies. The FDA removed semaglutide from the shortage list in late 2024; enforcement of 503B/503A compounding restrictions has tightened, though some 503A compounding continues for clinician-documented patient-specific medical necessity.
Semaglutide is not currently on the WADA prohibited list. It is not a controlled substance. International availability varies by country and regulatory agency.
Cost & Access
Semaglutide is broadly available through U.S. prescription channels under the Ozempic, Wegovy, and Rybelsus brand names, with manufacturer savings programs and insurance prior-authorization substantially reducing out-of-pocket cost for qualifying patients. International pricing varies widely by country.
Compounded semaglutide: Widely available during the FDA-declared shortage of 2022–2024; with the shortage resolved in late 2024, FDA enforcement of 503B/503A compounding restrictions has tightened and many compounding pharmacies have ceased semaglutide production. Some 503A compounded semaglutide remains available for clinician-documented patient-specific medical necessity.
Semaglutide is not on the Category 2 bulk substance list addressed by HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement. Semaglutide is an FDA-approved branded drug with established regulatory status; the regulatory question affecting its compounded supply is the FDA shortage list and the Novo Nordisk litigation against compounding pharmacies, not the Category 2 framework.
Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching semaglutide often also look at these:
SURMOUNT-5 head-to-head (NEJM 2025) — weight loss, CV outcomes, side effects, cost, and when to choose which.
Triple GLP-1 / GIP / glucagon agonist. The most potent obesity drug in Phase III, ~24% body weight reduction.
Daily GLP-1 receptor agonist (Victoza / Saxenda). First-generation GLP-1 with shorter half-life.
Fixed-dose combination of cagrilintide + semaglutide. Amylin + GLP-1 obesity protocol.
Oral small-molecule GLP-1 receptor agonist in Phase III for obesity and type 2 diabetes.
Dual GLP-1 / glucagon receptor agonist developed by Innovent / Eli Lilly, principally for Asian markets.
Key References
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641.
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702.
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PMID: 31767182.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186.
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417.
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728.
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945.
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209.
- Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364.
- Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use — Full Prescribing Information. FDA.gov.
Last updated: April 2026 | Profile authored by Kalios Peptides research team